-
公开(公告)号：US11787828B2
公开(公告)日：2023-10-17
申请号：US16982022
申请日：2019-03-18
发明人： Brian Lian , Hiroko Masamune , Geoffrey Barker
IPC分类号： C07F9/6574
CPC分类号： C07F9/65742 , C07B2200/13
摘要： Disclosed herein are methods of crystallizing the compound of Formula I, as well as crystalline forms thereof. Crystalline forms of Formula I disclosed include the TBME solvate crystalline form, toluene solvate crystalline form, ethanol solvate crystalline form, THF solvate crystalline form, EtOAc solvate crystalline form, acetone solvate crystalline form and crystalline Form C.
-
公开(公告)号：US20220016136A1
公开(公告)日：2022-01-20
申请号：US17311014
申请日：2019-12-04
发明人： Brian Lian , Hiroko Masamune
IPC分类号： A61K31/661 , A61K31/366 , A61K31/192 , A61K31/662 , A61K31/664 , A61K31/66 , A61K31/404 , A61K31/40 , A61K31/501 , A61K31/216 , A61K31/575 , A61K31/397 , A61K31/46 , A61K31/422 , A61K31/42 , A61K31/55 , A61K31/4184 , A61K31/554 , A61K31/495 , A61K31/4412 , A61K31/415 , A61K31/41 , A61K31/5377 , A61K31/341 , A61K31/4192 , A61K31/381 , A61K31/4709 , A61K31/498 , A61K31/553 , A61K31/4245 , A61K31/435 , A61K31/506 , A61K31/4353 , A61K31/551 , A61K38/26 , A61K38/28 , A61K38/18 , A61K45/06 , A61P1/16
摘要： The present disclosure is directed toward the use of thyroid receptor agonists of pharmaceutically acceptable salts thereof, in combination with a second pharmaceutical agent for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
-
公开(公告)号：US11951114B2
公开(公告)日：2024-04-09
申请号：US17738621
申请日：2022-05-06
发明人： Brian Lian , Rochelle Hanley , Misha Dinerman , Mark Erion , Serge Boyer , Hongjian Jiang
IPC分类号： A61K31/662
CPC分类号： A61K31/662
摘要： Methods useful for treating X-linked adrenoleukodystrophy are provided.
-
公开(公告)号：US11202789B2
公开(公告)日：2021-12-21
申请号：US16462515
申请日：2017-11-17
发明人： Brian Lian
IPC分类号： A61K31/665 , A61K31/662 , A61K31/683 , A61K45/06 , A61P9/00 , A61P43/00 , A61P41/00 , A61P3/10 , A61P3/08 , A61P1/16 , A61P3/06 , A61P35/00 , A61P3/04
摘要： The present disclosure provides methods and compositions for the treatment of hepatic symptoms of glycogen storage diseases through the administration of thyroid hormone receptor agonists. The methods and compositions provided herein are useful in the treatment of hyperlipidemia, hypercholesterolemia, hepatic steatosis, cardiomegaly, hepatomegaly, hepatic fibrosis, and cirrhosis associated with glycogen storage diseases (GSD) and defects of glycogen metabolism. Said compounds may also be useful in the prevention of GSD-related hepatocellular adenoma and hepatocellular carcinoma.
-
公开(公告)号：US12102646B2
公开(公告)日：2024-10-01
申请号：US17299998
申请日：2019-12-04
发明人： Brian Lian , Hiroko Masamune , Geoffrey E. Barker
IPC分类号： A61K31/662 , A61K31/665 , A61P1/16 , A61P11/00 , A61P17/02 , A61P29/00
CPC分类号： A61K31/662 , A61K31/665 , A61P1/16 , A61P11/00 , A61P17/02 , A61P29/00
摘要： The present disclosure is directed to methods of treating fibrotic conditions and inflammation by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.
-
公开(公告)号：US20240239843A1
公开(公告)日：2024-07-18
申请号：US18274952
申请日：2022-09-12
发明人： Brian Lian , Geoffrey E. Barker , Kader Yagiz , Maureen Barnes , Erland Stevens
CPC分类号： C07K14/001 , A61P1/16 , A61K38/00
摘要： Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions. pharmaceutical compositions. the use and preparation thereof.
-
公开(公告)号：US20240058415A1
公开(公告)日：2024-02-22
申请号：US18447990
申请日：2023-08-10
发明人： Brian Lian , Geoffrey E. Barker , Maureen Barnes , Kader Yagiz , Erland Stevens
摘要： Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.
-
公开(公告)号：US20230226038A1
公开(公告)日：2023-07-20
申请号：US18008425
申请日：2021-06-07
发明人： Brian Lian , Geoffrey E. Barker , Kader Yagiz , Maureen Barnes , Erland Stevens
IPC分类号： A61K31/46 , A61K31/53 , C07F9/6561 , C07D451/06 , A61K31/675 , A61P1/16
CPC分类号： A61K31/46 , A61K31/53 , C07F9/6561 , C07D451/06 , A61K31/675 , A61P1/16
摘要： The present disclosure is directed to FXR agonists, pharmaceutical compositions thereof, and methods of using the same for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis, either alone or in combination with thyroid receptor agonists.
-
公开(公告)号：US20220257618A1
公开(公告)日：2022-08-18
申请号：US17738621
申请日：2022-05-06
发明人： BRIAN LIAN , Rochelle Hanley , Misha Dinerman , Mark Erion , Serge Boyer , Hongjian Jiang
IPC分类号： A61K31/662
摘要： Methods useful for treating X-linked adrenoleukodystrophy are provided.
-
公开(公告)号：US20210024554A1
公开(公告)日：2021-01-28
申请号：US16982022
申请日：2019-03-18
发明人： Brian Lian , Hiroko Masamune , Geoffrey Barker
IPC分类号： C07F9/6574
摘要： Disclosed herein are methods of crystallizing the compound of Formula I, as well as crystalline forms thereof. Crystalline forms of Formula I disclosed include the TBME solvate crystalline form, toluene solvate crystalline form, ethanol solvate crystalline form, THF solvate crystalline form, EtOAc solvate crystalline form, acetone solvate crystalline form and crystalline Form C.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.023 秒)
